Behavioral Variant Frontotemporal Dementia
Behavioral variant frontotemporal dementia (bvFTD) is the most common clinical syndrome within the frontotemporal dementia (FTD) spectrum, accounting for approximately 60% of FTD cases. Unlike Alzheimer disease (AD), which typically presents with progressive episodic memory loss, bvFTD is defined by early and progressive changes in personality, social conduct, and executive function, with relative preservation of memory and visuospatial abilities. The onset is characteristically younger than in AD, with most patients presenting between ages 45 and 65, and the disease is the second most common cause of dementia in individuals younger than 65. The clinical overlap with primary psychiatric disorders and the absence of disease-specific biomarkers make bvFTD one of the most diagnostically challenging neurodegenerative conditions. Revised international consensus criteria published in 2011 (the Rascovsky criteria) provide a structured framework for diagnosis at possible, probable, and definite levels.
Bottom Line
- Most common FTD subtype: bvFTD accounts for ~60% of all FTD cases; FTD overall is the third most common degenerative dementia (prevalence ~15 per 100,000) and the second most common cause of dementia in patients <65 years
- Six core diagnostic features (Rascovsky 2011): Early behavioral disinhibition, apathy/inertia, loss of sympathy or empathy, perseverative/stereotyped/compulsive behavior, hyperorality and dietary changes, and executive dysfunction with relative sparing of memory and visuospatial function
- Diagnosis: Possible bvFTD requires ≥3 of 6 core features; probable bvFTD adds functional decline plus characteristic frontal/anterior temporal atrophy or hypometabolism on imaging; definite bvFTD requires histopathologic confirmation or a known pathogenic mutation
- Genetics: FTD is more heritable than AD — 10%–20% carry a known pathogenic variant; the three major genes are C9orf72 (most common, hexanucleotide repeat), GRN (progranulin), and MAPT (tau)
- Neuropathology: ~50% FTLD-TDP-43, ~45% FTLD-tau, ~5% FTLD-FUS; bvFTD is the least predictive of the FTD syndromes for underlying pathology
- Phenocopy syndrome: Patients meeting clinical bvFTD criteria but following a nonprogressive course with normal neuroimaging; most have psychiatric illness rather than neurodegeneration
- Treatment: No FDA-approved therapies; SSRIs for behavioral symptoms (disinhibition, compulsions, irritability); avoid cholinesterase inhibitors (may worsen symptoms); caregiver education and nonpharmacologic strategies are essential
Epidemiology
FTD has an overall prevalence of approximately 15 per 100,000 and is the third most common neurodegenerative dementia after AD and Lewy body dementia. Among patients younger than 65 years, FTD is the second most common cause of dementia. bvFTD accounts for the majority of FTD cases, with peak onset between ages 45 and 65 — only about one-quarter of patients present after age 65. An analysis of racial factors in FTD demonstrated greater disease severity and neuropsychiatric symptoms in Black patients compared with White or Asian patients. Compared with AD, FTD is more strongly associated with genetic risk: up to 43% of patients have a family history of dementia, ALS, or Parkinson disease, and 10%–20% carry a known pathogenic variant.
| Feature | bvFTD | Alzheimer Disease |
|---|---|---|
| Typical onset age | 45–65 years | Mid-70s to mid-80s |
| Presenting symptoms | Personality/behavioral change | Episodic memory loss |
| Early memory | Relatively preserved (~10% amnestic) | Prominently impaired |
| Visuospatial function | Relatively preserved | Variable impairment |
| Executive function | Early and prominent impairment | Later involvement |
| Insight | Severely impaired early | Variable, declines gradually |
| Imaging pattern | Frontal and anterior temporal atrophy | Hippocampal and parietal atrophy |
| Genetic contribution | 10%–20% known pathogenic variant | Lower monogenic proportion |
Rascovsky Diagnostic Criteria (2011)
The 2011 international consensus criteria define bvFTD across four diagnostic levels: neurodegenerative disease, possible bvFTD, probable bvFTD, and definite bvFTD. The criteria emphasize that behavioral and cognitive symptoms must be persistent or recurrent rather than single or rare events.
Six Core Diagnostic Features
Core Features of bvFTD (A–F)
- A. Early behavioral disinhibition: Socially inappropriate behavior (e.g., touching strangers), loss of manners or decorum, impulsive or rash actions (e.g., providing financial information to strangers)
- B. Early apathy or inertia: Loss of interest in previously enjoyed hobbies, spending most of the day lying in bed awake unless strongly encouraged to get up
- C. Early loss of sympathy or empathy: Diminished response to others' needs or feelings (e.g., staring blankly when a spouse becomes upset), reduced social interest and personal warmth
- D. Perseverative, stereotyped, or compulsive/ritualistic behavior: Simple repetitive movements (e.g., tracing circles), complex rituals (e.g., repeatedly flushing excessive toilet paper), stereotypy of speech
- E. Hyperorality and dietary changes: Altered food preferences, binge eating, increased alcohol or tobacco consumption, oral exploration or consumption of inedible objects (pica)
- F. Neuropsychological profile: Executive or generation deficits (impaired letter fluency, Trail Making Test Part B) with relative sparing of episodic memory and visuospatial skills
Diagnostic Levels
| Diagnostic Level | Requirements |
|---|---|
| Neurodegenerative disease | Progressive deterioration of behavior or cognition by observation or history from a knowledgeable informant |
| Possible bvFTD | ≥3 of 6 core features (A–F); symptoms must be persistent or recurrent |
| Probable bvFTD | Meets possible bvFTD criteria plus significant functional decline plus frontal/anterior temporal atrophy on MRI/CT or hypometabolism on PET/SPECT; AD biomarkers must be negative |
| Definite bvFTD | Meets possible or probable criteria plus histopathologic evidence of FTLD or a known pathogenic mutation |
Exclusionary Criteria
The pattern of deficits must not be better accounted for by a nondegenerative neurologic or medical disorder, and behavioral disturbance must not be better explained by a psychiatric diagnosis. For probable bvFTD (but not possible), biomarkers strongly indicative of AD or another neurodegenerative process must be negative.
Neuroimaging
Atrophy of the frontal and anterior temporal lobes is the imaging hallmark of bvFTD and may be visible on MRI early in the disease course. Atrophy patterns recapitulate the salience network, which integrates external and internal stimuli for the deployment of appropriate behaviors. This network includes the anterior cingulate cortex, anterior insula, striatum, amygdala, hypothalamus, and thalamus.
Regional Atrophy–Symptom Correlations
- Apathy: Medial frontal regions, especially the anterior cingulate cortex; dorsolateral frontal cortex also commonly involved
- Disinhibition: Related to asymmetry of frontal atrophy, especially in the ventral anterior insula and orbitofrontal cortex; severity correlates with the extent of right-sided atrophy
- Hyperorality/dietary changes: Right insula and orbitofrontal cortex atrophy
- Executive dysfunction: Dorsolateral frontal cortex and subcortical circuits
- FDG-PET: Frontal and anterior temporal hypometabolism; FDG-PET differs starkly between FTD and AD, making it valuable in ambiguous cases
- C9orf72 carriers: May show global, anterior-predominant atrophy that can be relatively symmetric; frontal hypometabolism on FDG-PET
Neuropathology
The term frontotemporal lobar degeneration (FTLD) refers to the histopathologic substrate of FTD clinical syndromes. Nearly all cases are classified by one of three abnormal proteins. bvFTD is the least predictive of the core FTD syndromes for underlying pathology — all three protein categories can produce the bvFTD phenotype.
| Pathologic Category | Frequency in FTD | Key Features | Clinical Clues |
|---|---|---|---|
| FTLD-TDP-43 | ~50% overall; >50% of bvFTD | Types A–D based on inclusion morphology and distribution; type A most common in C9orf72 and GRN | Concomitant motor neuron disease strongly suggests TDP-43; psychotic features (delusions, hallucinations) more common |
| FTLD-tau (MAPT) | ~45% overall; ~40% of bvFTD | 3R tau (Pick bodies) or 4R tau (CBD, PSP); not the mixed 3R/4R tau of AD | Atypical parkinsonism (rigidity, bradykinesia); apraxia of speech in nonfluent PPA |
| FTLD-FUS | ~5% | Neuronal cytoplasmic inclusions in deeper cortical layers and hippocampal dentate granule cells | Exclusively associated with bvFTD; very young onset (reported as young as 22 years); no strong family history; caudate atrophy; hyperorality, pica, rituals |
An important caveat is that AD pathology can underlie bvFTD. Pathologic case series estimate approximately 7% of bvFTD cases have AD pathology, though some studies report up to 40% AD biomarker positivity in clinically diagnosed bvFTD.
Genetics of bvFTD
FTD is more heritable than AD. The majority of monogenic FTD is caused by variants in three genes, although at least ten other genes have been implicated. Patients with familial FTD develop symptoms at a younger age than sporadic cases (mean 53.0 vs 57.8 years).
| Gene | Protein/Mechanism | Pathology | Clinical Features | Mean Onset | Imaging Pattern |
|---|---|---|---|---|---|
| C9orf72 | GGGGCC hexanucleotide repeat expansion (noncoding) | TDP-43 (types A, B, or mixed) | bvFTD and ALS (chief genetic cause of both); psychotic features (persecutory/somatoform delusions); late parkinsonism | 61.3 years | Relatively symmetric; frontal-predominant atrophy |
| GRN | Progranulin (haploinsufficiency) | TDP-43 (type A) | bvFTD most common phenotype; nonfluent PPA; highly variable within families; posterior cortical atrophy occasionally; no motor neuron disease | 58.2 years | Markedly asymmetric frontal, temporal, and parietal atrophy; side varies within families |
| MAPT | Microtubule-associated protein tau | FTLD-tau (filamentous tau inclusions) | Youngest onset; more disinhibition (vs apathy in GRN); semantic impairment common; anomia detectable presymptomatically; phenotypic variability within families (P301L) | 49.5 years | Relatively symmetric; temporal-predominant atrophy |
Genetic Counseling Considerations
- Genetic testing should always be accompanied by genetic counseling — ethical, legal, and cultural attitudes vary widely
- A positive family history does not always point to the same phenotype — relatives with very different clinical presentations (e.g., PPA in one family member and parkinsonism in another) may carry the same GRN variant
- Genetic variants may be identified even in patients with no apparent family history, particularly with C9orf72
- Presymptomatic detection is advancing: plasma neurofilament light chain rises ~30 years before symptom onset in C9orf72 carriers, and ~15 years before in GRN carriers
- Structural MRI may detect presymptomatic changes: temporal lobe volume changes ~6 years before symptoms in C9orf72, and frontal/temporal volume reductions ~1 year before symptoms in GRN
Differential Diagnosis
Distinguishing bvFTD from Psychiatric Disorders
The clinical overlap between bvFTD and primary psychiatric illness is one of the greatest diagnostic challenges in behavioral neurology. Bipolar affective disorder, axis II personality disorders, and late-onset schizophrenia may all present with behavioral changes that mimic bvFTD. Key distinguishing factors include the insidious, progressive nature of bvFTD, objective evidence of executive dysfunction on neuropsychological testing, and the presence of frontal/temporal atrophy on neuroimaging. Neurofilament light chain (NfL) in blood or CSF is particularly useful for differentiating FTD from primary psychiatric disease, as levels are elevated in neurodegeneration but normal in psychiatric conditions.
FTD Phenocopy Syndrome
A significant proportion of patients who meet clinical criteria for possible bvFTD follow a nonprogressive course. These patients, described as having the FTD phenocopy syndrome, typically have normal neuroimaging and most who have come to autopsy do not show evidence of neurodegeneration, though rare cases of very slow FTLD progression with confirmed pathology have been reported. The majority of phenocopy patients ultimately receive a psychiatric diagnosis.
Differential Diagnosis of bvFTD
- Alzheimer disease (frontal/behavioral variant): AD infrequently presents with a bvFTD-like syndrome indistinguishable on clinical grounds alone; AD biomarkers (amyloid PET, CSF Aβ/tau) are essential for differentiation; reported in up to 7%–40% of clinically diagnosed bvFTD
- Vascular dementia: Recurrent frontal or basal ganglia strokes may produce progressive apathy, disinhibition, or executive dysfunction; CADASIL is particularly difficult to distinguish from bvFTD
- Spontaneous intracranial hypotension: Frontotemporal brain-sagging syndrome can mimic bvFTD; usually accompanied by chronic headache; potentially treatable if the CSF leak source is identified
- Psychiatric illness: Late-onset bipolar disorder, axis II personality disorders, late-onset schizophrenia; NfL levels are normal in psychiatric disease
- FTD phenocopy syndrome: Nonprogressive clinical bvFTD with normal neuroimaging; most have underlying psychiatric rather than neurodegenerative disease
Biomarkers
Disease-specific biomarkers for FTLD are currently limited. In clinical practice, the primary role of biomarkers is to exclude AD and to support the presence of neurodegeneration. The identification of a known pathogenic variant remains the only method to establish definite FTLD pathology in a living patient.
| Biomarker | Utility in bvFTD | Limitations |
|---|---|---|
| Neurofilament light chain (NfL) | Elevated in blood and CSF; signals neuroaxonal loss; differentiates FTD from psychiatric disease; higher levels correlate with worse prognosis | Nonspecific — does not distinguish FTD from AD; elevated in multiple neurodegenerative conditions |
| FDG-PET | Frontal/anterior temporal hypometabolism; patterns differ starkly from AD (posterior temporoparietal pattern) | Cannot determine specific FTLD molecular pathology |
| Amyloid PET | Negative in FTLD; useful to exclude AD as the underlying cause of bvFTD syndrome | Does not confirm FTLD; a negative amyloid PET does not distinguish between FTD subtypes |
| Tau PET (flortaucipir) | Limited value; currently approved tracer exhibits off-target binding in patients with suspected TDP-43 pathology | Tracers specific for FTLD-associated tau isoforms and TDP-43 are still needed |
| RT-QuIC (real-time quaking-induced conversion) | May detect TDP-43 or tau pathology in CSF; originally applied to prion disease diagnosis | Research stage; requires CSF; not yet widely available for clinical use |
| Genetic testing | Identifies pathogenic variants in C9orf72, GRN, MAPT; confirms definite FTLD diagnosis | Requires genetic counseling; ethical and legal considerations; negative result does not exclude FTD |
FTD Spectrum Overlap Syndromes
The FTD spectrum extends beyond the three core syndromes (bvFTD, nonfluent variant PPA, semantic variant PPA) to include overlap with motor system disease. Approximately 15% of patients with FTD develop features of amyotrophic lateral sclerosis (ALS), and 30% of patients with ALS develop FTD features. FTD-ALS most commonly occurs with the behavioral variant. Concomitant motor neuron disease strongly suggests TDP-43 pathology. In some cases, features of bvFTD may coexist with features of primary progressive aphasia.
Pharmacologic Pitfalls in bvFTD
- Cholinesterase inhibitors are NOT recommended — cholinergic projections are largely intact in FTD, and these drugs may cause cognitive and behavioral worsening
- Antipsychotics: Patients with FTLD pathology are more sensitive to extrapyramidal side effects; if used, atypical agents are preferred over typical agents at the lowest effective dose, with weaning as soon as possible
- Memantine: Well tolerated but does not appear to provide clinical benefit in FTD
- Always consider the possibility of underlying AD pathology (up to 7%–40% of clinical bvFTD), which would change the treatment approach
Treatment
There are currently no FDA-approved disease-modifying treatments for FTD. Management is centered on nonpharmacologic behavioral strategies, caregiver education, and targeted off-label pharmacotherapy for symptoms that disrupt quality of life.
Nonpharmacologic Approaches
bvFTD imposes a greater caregiver burden than AD, with higher rates of stress and depression among caregivers and lower health-related quality of life. The DICE model (Describe, Investigate, Create, Evaluate) provides a structured approach to managing problem behaviors by identifying and modifying precipitating factors. Transcranial direct current stimulation may ameliorate behavioral symptoms but evidence remains preliminary.
Pharmacologic Management
| Medication Class | Agents | Target Symptoms | Notes |
|---|---|---|---|
| SSRIs | Sertraline, paroxetine, fluoxetine, citalopram | Disinhibition, irritability, compulsions, depression | Best evidence base for behavioral symptoms; serotonergic dysfunction correlates with impulsivity, irritability, abnormal eating |
| Trazodone | Trazodone | Irritability, agitation, depression, disordered eating | Serotonergic mechanism; supported by small randomized trial |
| Atypical antipsychotics | Olanzapine, aripiprazole, risperidone | Psychosis, agitation, anxiety | Use lowest effective dose; increased sensitivity to extrapyramidal effects; wean as soon as possible |
| Dopaminergic agents | Amphetamines, selegiline, amantadine | Apathy | Mesolimbic/mesocortical dopamine loss underlies apathy; limited evidence |
| Anticonvulsants | Carbamazepine, lamotrigine, topiramate | Inappropriate sexual behavior, aggression, hyperorality | Case report evidence only |
References
- Clark DG. Frontotemporal dementia. Continuum (Minneap Minn). 2024;30(6):1642-1672.
- Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477.
- Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615-1621.
- Seeley WW. Behavioral variant frontotemporal dementia. Continuum (Minneap Minn). 2019;25(1):76-100.
- Ducharme S, Dols A, Laforce R, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143(6):1632-1650.
- Power C, Lawlor BA. The behavioral variant frontotemporal dementia phenocopy syndrome: a review. J Geriatr Psychiatry Neurol. 2021;34(3):196-208.
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.
- Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266(8):2075-2086.
- Staffaroni AM, Quintana M, Wendelberger B, et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat Med. 2022;28(10):2194-2206.
- Katisko K, Cajanus A, Jaaskelainen O, et al. Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol. 2020;267(1):162-167.
- Seelaar H, Rohrer JD, Pijnenburg YAL, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82(5):476-486.
- Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20(9):789-797.
- Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149-156.
- Pijnenburg YAL, Sampson EL, Harvey RJ, Fox NC, Rossor MN. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry. 2003;18(1):67-72.